211 related articles for article (PubMed ID: 12936969)
21. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 1999 Jan; 43(1):79-86. PubMed ID: 10381104
[TBL] [Abstract][Full Text] [Related]
23. Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae.
Ibrahim KH; Hovde LB; Ross G; Gunderson B; Wright DH; Rotschafer JC
Diagn Microbiol Infect Dis; 2002 Nov; 44(3):265-71. PubMed ID: 12493174
[TBL] [Abstract][Full Text] [Related]
24. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Ambrose PG; Grasela DM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
[TBL] [Abstract][Full Text] [Related]
25. Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess.
Fernandez J; Barrett JF; Licata L; Amaratunga D; Frosco M
Antimicrob Agents Chemother; 1999 Mar; 43(3):667-71. PubMed ID: 10049285
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.
Lister PD
Antimicrob Agents Chemother; 2002 Jan; 46(1):69-74. PubMed ID: 11751113
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
[TBL] [Abstract][Full Text] [Related]
29. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
Croisier D; Etienne M; Bergoin E; Charles PE; Lequeu C; Piroth L; Portier H; Chavanet P
Antimicrob Agents Chemother; 2004 May; 48(5):1699-707. PubMed ID: 15105123
[TBL] [Abstract][Full Text] [Related]
30. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
MacGowan AP; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
[TBL] [Abstract][Full Text] [Related]
31. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections.
Amsden GW; Graci DM; Cabelus LJ; Hejmanowski LG
Chest; 1999 Jul; 116(1):115-9. PubMed ID: 10424513
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
33. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
Bast DJ; Dresser L; Duncan CL; Walker SE; Mandell LA; Low DE; de Azavedo JC
J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
35. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Andes D; van Ogtrop ML; Peng J; Craig WA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Lacy MK; Lu W; Xu X; Tessier PR; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1999 Mar; 43(3):672-7. PubMed ID: 10049286
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister PD; Sanders CC
Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
39. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
[TBL] [Abstract][Full Text] [Related]
40. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
